Drugs that target obesity and diabetes now account for an estimated 38% of all projected commercial inflows from the 2025 late-stage pipeline. Surging demand for weight loss and diabetes drugs leaves the pharmaceutical sector at risk from a "bubble effect" as profitability soars, new research suggests. Demand for the likes of Wegovy and Zepbound has driven research and development returns to their highest level in years, but a report published by Deloitte on Monday suggests this is masking pressure facing t ...